Pepaxto Adcom Saw Public Airing Of Unusual Level Of Discord Between US FDA, Oncopeptides

 
• By Sue Sutter

The four-hour virtual public meeting featured "incompatible" views of the FDA and sponsor on the OCEAN data, not to mention signs of impatience and resentment, with each side criticizing the positions of the other over the safety and efficacy of the multiple myeloma drug.

Thumbs up and down
The FDA and Oncopeptides seemed to agree on little at the recent ODAC meeting on Pepaxto. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers